Therapeutic blockade of PD-1 or PD-L1 using monoclonal antibodies (mAbs) have demonstrated encouraging responses in patients with melanoma, non-small cell lung cancer (NSCLC), as well as renal cell and bladder cell carcinoma [10]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.